Delivery Order SPE2DB22D2211-SPE2DB25FSCBF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- The Defense Logistics Agency awarded a $11,661.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with an ultimate completion date of August 14, 2025. Zepbound is a tirzepatide injection used for weight management, and this delivery order represents a competitive procurement with no set-aside designation. The award was placed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $2,045.91 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication, reflecting...
- The Defense Logistics Agency awarded a $3,544.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under...
- The Defense Logistics Agency awarded a $1,525.16 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Zepbound 10 mg/0.5 mL pen injectors with a completion date of July 30, 2025. This is a firm fixed price delivery order with no set-aside designation, executed under competitive procurement processes. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a tirzepatide-based injectable medication...
- The Defense Logistics Agency awarded a $15,525.98 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injections on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors valued at $2,426.10. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCBFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $81,521.82. This firm fixed-price delivery order represents a non-competitive award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is due for completion by August 4, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a prescription medication indicated for chronic weight management in adults with obesity or overweight conditions. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health System. The company's extensive portfolio of federal contracts with the Defense Logistics Agency demonstrates its capability to supply a comprehensive range of pharmaceutical products, specialty medications, and medical supplies to support military healthcare programs globally. This delivery order is consistent with the company's established role as a pharmaceutical prime vendor supporting the Department of Defense's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $81.5k | 8/1/25 |